secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2026-06-09T11:03:35+00:00
Accession:  0001193125-26-262950
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GSK to acquire Nuvalent for $124/share (~$10.6B); assets under FDA review for 2026 approval
--------------------------------------------------------------------------------

- All-share tender offer at $124.00 per share; aggregate equity value ~$10.6B; net cash investment ~$9.4B.
- 40% premium to last closing price; 26% premium to 30-day VWAP; no financing condition.
- Deal includes late-stage ROS1 inhibitor zidesamtinib and ALK inhibitor neladalkib; FDA decisions due Sept/Nov 2026.
- Supporting stockholders (~28% of Class A shares) have agreed to tender; termination fee $350.5M.
- Transaction expected to close Q3 2026; GSK expects accretion to operating profit in 2027, EPS in 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000119312526262950/0001193125-26-262950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000119312526262950/d137459d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-262950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer